Why the study?
Pulmonary hypertension is commonly seen in adults with congenital heart disease, where PAH therapies improve quality of life and prognosis, warranting a review of management and advanced therapies.
Answers are grounded in this paper and cite their sources.
Advanced PAH-specific therapies targeting the nitric oxide, endothelin, and prostacyclin pathways offer significant clinical benefits for patients with PAH associated with congenital heart disease.
Background Pulmonary hypertension (PH) is commonly seen in adults who have congenital heart disease (CHD). Therapy is available for pulmonary arterial hypertension (PAH) and has greatly benefitted many patients with PAH related to CHD (PAH-CHD) over the last 15 years, with evidence of improved quality of life and prognosis in those with Eisenmenger syndrome and repaired PAH-CHD. In this review, we describe the standard management and advanced therapies for PAH, which are available in specialist PH centres around the UK and Ireland, and how these are used in PAH-CHD. Decisions around the choice of therapy are governed by commissioning and available evidence. Conclusion We explain the different pathways for action and the variety of medications now at our disposal to help this important group of patients.
No takes yet. Share an insight, caveat, or question.
Liew et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: